For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Mycobacterium tuberculosis Thioredoxin Reductase Is Essential for Thiol Redox Homeostasis but Plays a Minor Role in Antioxidant Defense.

TitleMycobacterium tuberculosis Thioredoxin Reductase Is Essential for Thiol Redox Homeostasis but Plays a Minor Role in Antioxidant Defense.
Publication TypeJournal Article
Year of Publication2016
AuthorsLin K, O'Brien KM, Trujillo C, Wang R, Wallach JB, Schnappinger D, Ehrt S
JournalPLoS Pathog
Volume12
Issue6
Paginatione1005675
Date Published2016 06
ISSN1553-7374
KeywordsAnimals, Bacterial Proteins, Disease Models, Animal, Female, Homeostasis, Immunoblotting, Mice, Mice, Inbred C57BL, Mycobacterium tuberculosis, Oligonucleotide Array Sequence Analysis, Oxidation-Reduction, Oxidative Stress, Thioredoxin-Disulfide Reductase, Tuberculosis
Abstract

Mycobacterium tuberculosis (Mtb) must cope with exogenous oxidative stress imposed by the host. Unlike other antioxidant enzymes, Mtb's thioredoxin reductase TrxB2 has been predicted to be essential not only to fight host defenses but also for in vitro growth. However, the specific physiological role of TrxB2 and its importance for Mtb pathogenesis remain undefined. Here we show that genetic inactivation of thioredoxin reductase perturbed several growth-essential processes, including sulfur and DNA metabolism and rapidly killed and lysed Mtb. Death was due to cidal thiol-specific oxidizing stress and prevented by a disulfide reductant. In contrast, thioredoxin reductase deficiency did not significantly increase susceptibility to oxidative and nitrosative stress. In vivo targeting TrxB2 eradicated Mtb during both acute and chronic phases of mouse infection. Deliberately leaky knockdown mutants identified the specificity of TrxB2 inhibitors and showed that partial inactivation of TrxB2 increased Mtb's susceptibility to rifampicin. These studies reveal TrxB2 as essential thiol-reducing enzyme in Mtb in vitro and during infection, establish the value of targeting TrxB2, and provide tools to accelerate the development of TrxB2 inhibitors.

DOI10.1371/journal.ppat.1005675
Alternate JournalPLoS Pathog
PubMed ID27249779
PubMed Central IDPMC4889078
Grant ListR01 AI063446 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587